Compare Nuwellis Inc (NUWE) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Synchrony Financial — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while Synchrony Financial trades at $73.83 (market cap $23.40B). The key difference: Synchrony Financial is far larger — about 10636.4× Nuwellis Inc's market cap, and Synchrony Financial pays a 1.89% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Synchrony Financial for 28 Days on average.
| NUWE | SYF | |
|---|---|---|
Market Cap | $2.20M | $23.40B |
Volume | 121,544 | 2,108,179 |
Sector | Health | Financials |
52-Week High | $146.65 | $88.47 |
52-Week Low | $0.68 | $63.78 |
Typical Hold Time | 26 Days | 28 Days |
Enterprise Value | -$1.52M | $23.64B |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
SYF trades at $71.93, down 0.32% on the day, with a bearish technical signal from moving averages. The stock is valued attractively with a P/E of 7.38 and P/S of 1.68, supported by strong profitability including a 23.4% net income margin and 22.23% ROE. Recent earnings have consistently beaten estimates, and the company is expanding through partnerships like the Vetspire tie-up and OpenAI collaboration to enhance its digital payment solutions.
The outlook remains positive given the low valuation, high profitability, and strategic growth initiatives. Key risks include potential credit quality deterioration amid economic uncertainty and heavy investing cash outflows. Analyst consensus is bullish with a $88.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
